I. Introduction
Magnesium is the second most common intracellular cation. It is required for insulin secretion, insulin receptor interaction, post receptor events (involving tyrosine kinase mediated phosphorylation) and normal carbohydrate utilization (by Mg dependent enzymes) (1) . Magnesium is required for the activation of lipoprotein lipase and lecithin cholesterol acyl transferase which plays an important role in increasing HDL cholesterol and catabolism of triglycerides (2) . So magnesium deficiency leads to increase in LDL-C (low density lipoproteins), VLDL (very low density lipoproteins) and decrease in HDL-C (high density lipoproteins). Magnesium is also a vital factor for apolipoprotein synthesis [3] . Itmainly formscomplexes with ATP. This ATP-Mg complex is the allosteric factor for the enzyme HMG-CoA reductase in cholesterol synthesis. Therefore, magnesium is called as natural statin [4, 5] .Pyrophosphatase plays an important role in the first reaction of lipolysis and magnesium is a cofactor for it [6] . In hypomagnesemia situations, these enzymes are defective and lead to dyslipidemia. Hence, in the present study we have decided to observe the association between hypomagnesemia and dyslipidemia in patients with type 2 diabetes mellitus patients.
II.

Materials And Methods
The present study was conducted in the Department of Biochemistry, Nizam's Institute of Medical Sciences (NIMS), Hyderabad, India. Further, we have taken informed consent from the participating subjectsand followed Institutional Ethics committee protocol. Our study comprised of two groups. Case group consisted of Type 2 diabetes mellitus patients of both genders andcontrolgroup consisted of age and sex-matched apparently healthy subjects. Inclusion criteria are age above 30 years and with type 2 diabetes patients and on treatment with either oral hypoglycemic agents (OHA) or insulin.Patients on diuretics and presence of other chronic or acute infections were excluded from the study. Moreover, patients who areon phenothiazines, caffeine, nicotine, levodopa, morphine, steroids, oral contraceptives, alpha-interferon etc., were excluded.
Blood samples were collected from 86 study participants in the fasting state. Duration of diabetes, drug history, and BMI were recorded. Fasting plasma glucose, serum levels of magnesium (Mg), creatinine, urea and lipid profile were measured by standard methods. Glycatedhemoglobin was measured by HPLC method. Statistical analyses were performed with graph pad prism 5 version. Results were expressed as mean±SD when the data is parametricand median (range) when the data is nonparametric. The two groups are compared using unpaired t test and Mann-Whitney U test when data is parametric and non-parametric respectively. P<0.05 is taken as significant.
III. Results
This is a case-control study comprising of 86 subjects, of which 50 patients were diabetic and 36 patients were apparently healthy controls. Baseline characteristics Control group consisted of 36 healthy subjects, out of which15 were females (41%) and 21 were males (59%). Similarly, among 50 diabetic patients in the case group, 20 were females (40%) and 30 were males (60%). The median value of BMI in diabetic patients issignificantly higher in cases (27kg/m ² ) when compared to controls (24kg/m²). The median value of fasting plasma glucose level in cases and controls is 125mg/dl and 80mg/dl respectively and it is significantly (p<0.0001) higher in cases than controls. SimilarlyGlycatedHemoglobin also showed higher levels in cases compared tocontrols which were statistically significant ( Table 2) .Among the lipid parameters the median triglycerides and total cholesterol to HDL-C ratio is significantly higher in cases than in controls (p=0.008, p=0.02) respectively. The mean value of atherogenic index of plasma(AIP) in cases and controls is 0.5 and 0.3 respectively and it is significantly (p<0.0001) higher in cases. There is no statistically significant difference in serum Total cholesterol, LDL-C and HDL-C in cases and controls.The median value of serum magnesium level in cases and controls is 0.8mmol/L and 1.0mmol/L respectively and it is significantly (p=0.0001) lower in cases than in controls. Serum magnesium has significant negative correlation with Total cholesterol (P=0.006), LDL-C (P=0.03), TC/HDL (P=0.04) and HbA1C (P=0.002) as shown in Table 3 . 
Biochemical investigations
Discussion
Several studies showed that there is an association between lipid metabolism disorders and magnesium deficiency in type 2 diabetes patients [7] [8] [9] .In the present study we found an increase in serum triglyceride levels, total cholesterol to HDL ratio and atherogenic index of plasma in case group when compared to control group and also we found significant decrease in magnesium levels in cases when compared to controls. It suggests that magnesium deficiency can contribute to dyslipidemia.
In this study, we observed significant negative correlation of serum magnesium with total cholesterol,LDL cholesterol and total cholesterol HDL-C ratio. This is similar to the study done by Sasmita Mishra et al (10) . This might point out the contributory role of magnesium towards dyslipidemia. The present study reports no correlation between serum magnesium and HDL cholesterol, serum triglycerides. Hamid Nasri and his colleagues also did not show anyassociation between these parameters [11] . Magnesium deficiency inactivates lipid metabolismenzymes which in turn lead to dyslipidemia. It is a cofactor for several enzymes involved in carbohydrate metabolism and its imbalance has been implicated in diabetes mellitus both as a cause and a consequence. In the gut, magnesium creates insoluble complexes with fatty acids and prevents the dietary fat absorption [12] .
A significant negative correlation was found between serum magnesium and glycemic control. Magnesium is important for the effectiveness of insulin. Hypomagnesemia results in a defective tyrosine kinase [13, 14] . Oral magnesium administration had caused a fall in total cholesterol levels, LDL cholesterol levels, triglyceride levels and increase in HDL cholesterol levels [15, 16] . It has been proved in several studies that daily oral magnesium supplementation substantially improved insulin sensitivity by 10 % and reduced blood sugar by 37 % (17).
IV. Conclusion
The current study shows hypomagnesemia and dyslipidemia in type 2 diabetic patients in comparison with healthy individuals. We observed significant negative correlation of magnesium with total cholesterol and LDL-C which might point out the contributory role of magnesium towards dyslipidemia. Studies with oral supplementation will be helpful to confirm the causative role of magnesium deficiency in the development of dyslipidemia.
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